PCSK9 and cardiovascular disorder: Such delivery systems have already been developed to target the liver, taking advantage of the exclusive expression of the asialoglycoprotein receptor on hepatocytes, and hepatocyte-targeted modulation of PCSK9 by Inclirisan has recently been approved by the FDA to reduce cardiovascular disease risk.32